Vascular inflammation and low‐density lipoproteins: is cholesterol the link? A lesson from the clinical trials
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
For long time, the role of LDL and inflammation in the pathogenesis of atherosclerosis have been studied independently from each other and only more recently a common platform has been suggested. Accumulation of excess cholesterol due to the presence of increased circulating LDL promotes endothelium dysfunction and activation, which is associated with increased production of pro‐inflammatory cytokines, overexpression of adhesion molecules, chemokines and C‐reactive protein (CRP), increased generation of reactive oxygen species and reduction of nitric oxide levels and bioavailability. All these processes favour the progressive infiltration of inflammatory cells within the arterial wall where cholesterol accumulates, both extracellularly and intracellularly, and promotes vascular inflammation. According to this, lipid‐lowering therapies should improve inflammation and, indeed, statins decrease circulating inflammatory markers such as CRP and improve endothelial function and plaque burden. Pleiotropic activities have been proposed to explain this effect. However, mendelian randomization studies ruled out a direct role for CRP on coronary artery disease and studies with other lipid lowering drugs, such as ezetimibe showed that the beneficial effect of LDL‐cholesterol‐lowering therapies on systemic inflammatory status, as monitored by changes in CRP plasma levels, could be achieved, independently of the mechanism of action, only in patients presenting with baseline inflamed conditions. These observations strengthen the direct link between cholesterol and inflammation and indicate that decreasing LDL levels is one of the key goals for improving cardiovascular outcome. Linked Articles: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734 · cited 1×
“It is synthesized by the liver in response to IL-6 and is a wellestablished marker of inflammation (Pepys and Hirschfield, 2003) whose levels significantly increase in response to inflammatory stimuli (Gabay and Kushner, 1999).”
BackgroundRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 7×
“This study investigated approximately 17 800 patients with median LDL-C of 108 mg·dL 1 but elevated hs-CRP (>2.0 mg·L 1) (Ridker et al., 2008) which were treated with rosuvastatin (20 mg) or placebo.”
BackgroundMethodInfluentialEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
(2010) · The Lancet · doi:10.1016/s0140-6736(09)61717-7 · Cited by 2,546 · cited 2×
“…meta-analysis from 54 long-term prospective studies reported a continuous associations of plasma CRP levels with coronary heart disease (CHD) risk (Kaptoge et al., 2010), further supporting the concept that CRP could be a powerful risk biomarker for first and recurrent cardiovascular (CV) events…”
BackgroundEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 2×
“While it could appear surprising that PCSK9 inhibitors, which decrease LDL-C levels up to 60% (Robinson et al., 2015; Sabatine et al., 2015), do not affect CRP levels, also in the placebo arm (statins and/or ezetimibe treated patients) of almost all clinical trials, no significant changes in CRP plasma levels were obs…”
BackgroundC-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292 · cited 1×
“…and the PROVE IT-TIMI 22 study, the best outcomes were observed in patients who reached both an LDL-C less than 70 mg·dL 1 and an hs-CRP less than 2.0 mg·L 1, with even greater benefit in those individuals in which the hs-CRP was less than 1.0 mg·L 1 (Ridker et al., 2005; Morrow et al., 2006).”
BackgroundInfluentialRidker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481 · cited 4×
“, 2004), by increasing very low density lipoprotein (VLDL) production and secretion by the liver, paralleled by a decreased clearance of TG-rich lipoproteins, with the net effect of increasing serum TG levels (Khovidhunkit et al., 2004).”
InfluentialA Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233 · cited 2×
“The role of cholesterol (the ‘cholesterol era’) and that of cholesterolcarrying LDL (the ‘LDL era’) in the formation of atherosclerotic plaques has been extensively evaluated starting from the beginning of the 20th century and was validated by the discovery of the LDL receptor (Linton et al., 2000; Goldstein and Brown…”
BackgroundNicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178 · cited 6×
“Of note, even in patients where CRP is below 2 mg·L 1 and not altered by the therapy, such as in the GLAGOV study, LDL-C reduction with anti-PCSK9 antibodies results in atherosclerotic plaque regression as determined by IVUS (Nicholls et al., 2016).”
BackgroundMethodResultInfluential(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146 · cited 1×
“This is suggestive of an attenuation of the IL-6/IL-6R axis signalling in carriers of this variant; indeed this IL6R SNP was associated with a decreased CHD risk (Sarwar et al., 2012; Swerdlow et al., 2012).”
BackgroundMacrophage Phenotype and Function in Different Stages of Atherosclerosis
Tabas, I., & Bornfeldt, K. E. (2016) · Circulation Research · doi:10.1161/circresaha.115.306256 · Cited by 1,121 · cited 2×
“…inflammasome (Grebe and Latz, 2013), which might favour the instauration and amplification of a local and systemic immuno-inflammatory response (Tabas and Bornfeldt, 2016), characterized by the production of several pro-inflammatory cytokines; among them, C-reactive protein (CRP), IL-6 and…”
BackgroundRajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039 · cited 9×
“The central role of IL-1 in inflammation has been confirmed by studies with agents targeting IL-1 activity, such as anakinra (an IL-1 receptor antagonist), which decreased CRP production in acute coronary syndrome patients (Abbate et al., 2010; Abbate et al., 2013; Morton et al., 2015), but failed to reduce the risk o…”
BackgroundInfluentialRidker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010 · cited 1×
“…observation that the greatest reduction in CV events was in the treatment group that achieved both LDL-C less than 70 mg·dL 1 and hs-CRP less than 2 mg·L 1 (65% reduction), compared with only a 33% risk reduction in patients that achieved one or neither target (P 0.0001) (Ridker et al., 2009).”
BackgroundInfluentialGenetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756 · cited 1×
“…effects on CRP reduction and the few available data do not show a robust correlation between the magnitude of LDL-C reduction and that of CRP (Flaim et al., 2014; Stroes et al., 2014; Cannon et al., 2015; Hovingh et al., 2015; Raal et al., 2015a, b; Nicholls et al., 2016; Sahebkar et al., 2016).”
BackgroundC Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) · BMJ · doi:10.1136/bmj.d548 · Cited by 642 · cited 6×
“A large meta-analysis from 54 long-term prospective studies reported a continuous associations of plasma CRP levels with coronary heart disease (CHD) risk (Kaptoge et al., 2010), further supporting the concept that CRP could be a powerful risk biomarker for first and recurrent cardiovascular (CV) events (Koenig, 2013).”
BackgroundInfluentialAnti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315 · cited 2×
“…from 54 long-term prospective studies reported a continuous associations of plasma CRP levels with coronary heart disease (CHD) risk (Kaptoge et al., 2010), further supporting the concept that CRP could be a powerful risk biomarker for first and recurrent cardiovascular (CV) events (Koenig, 2013).”
BackgroundHow Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
Welty, F. K. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0400-4 · Cited by 221 · cited 1×
“Small dense LDL enter the arterial intima more easily (Diffenderfer and Schaefer, 2014), and are more prone to oxidation while small dense HDL possess a limited antioxidant and anti-inflammatory activity (Welty, 2013).”
BackgroundTargeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Self-citationSahebkar, A., Di Giosia, P., Stamerra, C. A., Grassi, D., Pedone, C., Ferretti, G., Bacchetti, T., Ferri, C., & Giorgini, P. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12905 · Cited by 116 · cited 2×
“…effects on CRP reduction and the few available data do not show a robust correlation between the magnitude of LDL-C reduction and that of CRP (Flaim et al., 2014; Stroes et al., 2014; Cannon et al., 2015; Hovingh et al., 2015; Raal et al., 2015a, b; Nicholls et al., 2016; Sahebkar et al., 2016).”
BackgroundNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99 · cited 2×
“lipoproteins, such as lomitapide or mipomersen (Norata et al., 2013), as well as those increasing LDL-C metabolism, such as inhibitors of the proprotein convertase subtilisin/kexin type 9 (PCSK9) (Norata et al.”
BackgroundSelf-citationGenetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
Elliott, P. (2009) · JAMA · doi:10.1001/jama.2009.954 · Cited by 35
Cited by
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
Willeit, P., Tschiderer, L., Allara, E., Reuber, K., Seekircher, L., Gao, L., Liao, X., Lonn, E., Gerstein, H. C., Yusuf, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046361 · Cited by 452
Inflammation, not Cholesterol, Is a Cause of Chronic Disease
Tsoupras, A., Lordan, R., & Zabetakis, I. (2018) · Nutrients · doi:10.3390/nu10050604 · Cited by 315
Potì, F., Santi, D., Spaggiari, G., Zimetti, F., & Zanotti, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020351 · Cited by 253
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
Metadata
- Authors
- Catapano, A. L., Pirillo, A., & Norata, G. D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-05-05
- Volume
- 174
- Issue
- 22
- Pages
- 3973-3985
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2601492960
- Cited by
- 137
- References
- 29
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.